ライフサイエンスコーパス: osteopenia

1 to identify patients with sarcopenia and/or osteopenia.

2 teopenia, and 1 year for women with advanced osteopenia.

3 arly-onset seizures, cerebellar atrophy, and osteopenia.

4 eased bone resorption is responsible for the osteopenia.

5 osteoblastic differentiation, causing severe osteopenia.

6 would prevent or treat parenteral nutrition osteopenia.

7 consequence, these mutant mice showed severe osteopenia.

8 tive osteoblast-mediated bone formation, and osteopenia.

9 analysis, three presented with osteoporosis/osteopenia.

10 ssion inhibits osteoblastogenesis and causes osteopenia.

11 Nov transgenic mice exhibited osteopenia.

12 o and in vivo, and its overexpression causes osteopenia.

13 Mice lacking GPR103A expression display osteopenia.

14 with AN and the mechanisms of recovery from osteopenia.

15 bisphosphonates given for malignancy-related osteopenia.

16 1) have a high incidence of osteoporosis and osteopenia.

17 e and bone mass and resultant sarcopenia and osteopenia.

18 isingly, reversed the CKD-induced trabecular osteopenia.

19 ion from differentiated osteoblasts leads to osteopenia.

20 quol production in postmenopausal women with osteopenia.

21 fects including weight gain, ecchymosis, and osteopenia.

22 osteoblasts, but not in osteoclasts, causes osteopenia.

23 a negative bone balance and causing profound osteopenia.

24 systemic complications such as IL-6-mediated osteopenia.

25 ven heparin during multiple cycles developed osteopenia.

26 rate is likely a consequence of accelerated osteopenia.

27 These mice developed a reversible osteopenia.

28 the differential diagnosis and management of osteopenia.

29 accelerated mouse as a model of involutional osteopenia.

30 ur were measured with CT in 37 children with osteopenia.

31 they exhibited cancellous and cortical bone osteopenia.

32 history includes diabetes, hypertension, and osteopenia.

33 d tumors, and other medical problems such as osteopenia.

34 including propensity to fractures and severe osteopenia.

35 , T12, and throughout the axial skeleton and osteopenia.

36 of MAGP1 does not exacerbate MAGP1-dependent osteopenia.

37 Cre(+/-);Hey2(Delta/Delta) females developed osteopenia.

38 differentiated and mature osteoblasts causes osteopenia.

39 compared with a group with no sarcopenia or osteopenia.

40 xidative damage in postmenopausal women with osteopenia.

41 (95% CI, 1.0 to 1.3) for women with advanced osteopenia.

42 The prevalence of osteopenia (-1.0 SD >/= T-score > -2.5 SD) and osteoporo

43 pectively diagnosed with both sarcopenia and osteopenia, 167 with sarcopenia only, 48 with osteopenia

44 y unremarkable, but may reveal periarticular osteopenia 3-6 weeks after the onset of clinical symptom

45 s (95% CI, 13.9 to 21.5) for women with mild osteopenia, 4.7 years (95% CI, 4.2 to 5.2) for women wit

46 .1% vs 11.2%), hypertension (9.8% vs 18.4%), osteopenia (41.5% vs 43.1%), fractures (11.3% vs 18.6%),

47 s for women with normal bone density or mild osteopenia, 5 years for women with moderate osteopenia,

48 king Shn3 are completely resistant to disuse osteopenia, a process that requires functional osteoclas

49 eton reveals that mutant mice develop severe osteopenia accompanied by focal lytic and sclerotic lesi

50 stress disorder, hypertension, diabetes, and osteopenia, among others.

51 ausal women with osteoporosis or significant osteopenia and a mean age of 64 y underwent (18)F-fluori

52 Severe osteopenia and altered bone architecture were found in y

53 re we examined how PSTPIP2 deficiency causes osteopenia and bone lesions, using the mouse PSTPIP2 mut

54 e have a normal life span but exhibit severe osteopenia and compromised bone repair in adult mice bec

55 collagen in bone fibrils contributes to the osteopenia and decreased bone strength in mice with the

56 in an osteodysplasia characterized by severe osteopenia and down-regulation of osteoblast differentia

57 spleen, and bone marrow, but the generalized osteopenia and focal bone lesions present in many adult

58 In addition, juxta-articular osteopenia and focal erosion of marginal and subchondral

59 te, which eventually leads to short stature, osteopenia and fractures.

60 ancer; low levels of vitamin D contribute to osteopenia and fractures; and low levels of the antioxid

61 d human MCV autoantibodies into mice induced osteopenia and increased osteoclastogenesis.

62 pecific for distinguishing osteoporosis from osteopenia and normal BMD.

63 t anaphylaxis, or patients with osteoporosis/osteopenia and normal bone mineral density.

64 RECENT FINDINGS: Increased rates of osteopenia and osteoporosis are seen in the HIV populati

65 Accelerated bone resorption leading to osteopenia and osteoporosis has been noted in human immu

66 etabolism can result in decreased bone mass (osteopenia and osteoporosis) or impaired mineralization

67 ng hypercalciuria have a higher incidence of osteopenia and osteoporosis, measured by the dual-energy

68 tial treatment of skeletal diseases, such as osteopenia and osteoporosis.

69 forms of metabolic bone diseases, including osteopenia and osteoporosis.

70 ody of literature showing increased rates of osteopenia and osteporosis in the HIV population.

71 pport a weak association between generalized osteopenia and periodontal disease.

72 pretransplant fracturing and the severity of osteopenia and posttransplant glucocorticoids.

73 use chow (ASC content = 0) but suffer severe osteopenia and spontaneous fractures with stresses that

74 on in an adult mouse leading to low-turnover osteopenia and suggest that Runx2-I and II have distinct

75 MR images accurately reflected the degree of osteopenia and trabecular thinning noted around the cruc

76 e resembling accelerated aging that includes osteopenia and vascular calcifications.

77 M) women exhibiting mild systemic bone loss (osteopenia) and local bone loss (periodontitis) reduced

78 Loss of bone mass (osteopenia) and loss of muscle mass (sarcopenia) that oc

79 osteopenia, 5 years for women with moderate osteopenia, and 1 year for women with advanced osteopeni

80 (95% CI, 4.2 to 5.2) for women with moderate osteopenia, and 1.1 years (95% CI, 1.0 to 1.3) for women

81 neration of cataracts, development of severe osteopenia, and accelerated closure of dermal wounds.

82 ly-onset periodontitis and root resorption), osteopenia, and acro-osteolysis.

83 ng effects on bone mass: Oxtr(-/-) mice have osteopenia, and Avpr1alpha(-/-) mice display a high bone

84 atal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones.

85 Osteoporosis, osteopenia, and bone fracture are particularly common in

86 de electrocardiographic findings, scoliosis, osteopenia, and motor control.

87 Risks of osteoporosis, osteopenia, and nonspine fractures were significantly hi

88 ds existed for higher risks of osteoporosis, osteopenia, and nonspine fractures with higher percentag

89 s and strength, increased fat mass, frailty, osteopenia, and osteoporosis.

90 ncer survivors who may be at higher risk for osteopenia, and subsequently osteoporosis.

91 lowed by oral bisphosphonates for those with osteopenia, and universal treatment with oral bisphospho

92 ls of classic estrogen action (uterotrophic, osteopenia, and vasomotor instability models) and yet we

93 n may be at risk for low serum calcidiol and osteopenia; and that routine monitoring of risk and cons

94 honate therapy in women with osteoporosis or osteopenia; and universal bisphosphonate therapy.

95 honate therapy in women with osteoporosis or osteopenia; annual BMD screening and selective bisphosph

96 In conclusion, cholestatic osteopenia appears to result from a combination of decre

97 ice exhibit systemic inflammation and severe osteopenia ( approximately 60% lower bone mass) similar

98 To determine whether sarcopenia and/or osteopenia are associated with 1-year mortality in an ol

99 Osteoporosis and osteopenia are characterized by reductions in bone mass

100 However, although patients with pre-existing osteopenia are likely to require monitoring and bone-pro

101 , although the mechanisms that contribute to osteopenia are not completely understood.

102 attachment loss, implicating postmenopausal osteopenia as a risk indicator for periodontal disease i

103 mography (CT) scans to assess sarcopenia and osteopenia as indicators of underlying frailty may provi

104 As a result, these mice developed severe osteopenia as they aged.

105 vere skeletal muscle wasting, emphysema, and osteopenia, as well as generalized atrophy of the skin,

106 Sarcopenia and/or osteopenia, assessed via total cross-sectional muscle ar

107 bone remodeling, and its absence results in osteopenia associated with an increase in osteoclast num

108 inversion in osteoblasts led to generalized osteopenia associated with enhanced bone resorption in t

109 ese include stress and coping behaviors, and osteopenia associated with estrogen deficiency.

110 vely severe MFS (Fbn1(mgR/mgR) mice) develop osteopenia associated with normal osteoblast differentia

111 and increased bone resorption and developed osteopenia at 6 months of age.

112 In both sexes, the odds for osteoporosis or osteopenia at each of the femoral sites increased by 10-

113 dified AHA-DLS, the odds for osteoporosis or osteopenia at the trochanter, total hip, and lumbar spin

114 in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.

115 es characteristic of senescence that include osteopenia, atrophic skin, hepatocellular degeneration,

116 ores and were glucose intolerant with severe osteopenia because of defective osteoblastogenesis and s

117 characterized by defective type I collagen, osteopenia, bone fragility, severe bony deformities, and

118 postmenopausal women who have low bone mass (osteopenia) but do not have osteoporosis or a history of

119 ot only stimulated bone turnover, leading to osteopenia, but also suppressed bone matrix mineralizati

120 Osteopenia by itself is not an indication for treatment.

121 l vein ameliorates ovariectomy (OVX)-induced osteopenia by reducing T-helper 1 (Th1) and T-helper 17

122 Bone density in this range was termed "osteopenia" by a World Health Organization working group

123 ly Wnt coreceptor, results in low bone mass (osteopenia) by decreasing bone formation.

124 The osteopenia can be accounted for by a >100% increase in t

125 that Gja1(Jrt)/+ mice exhibited early-onset osteopenia caused by activation of osteoclasts secondary

126 In a mouse model of spontaneous osteopenia caused by hyperactivation of STAT1/3 signalin

127 ereas heterozygous Pkd1m1Bei mutant mice had osteopenia caused by reduced osteoblastic function.

128 Is this patient at greater risk of osteopenia, characterized by a T-score between -1.0 and

129 are at higher risk for both osteoporosis and osteopenia compared with healthy controls, and that fema

130 ses MMPs to favor adipogenesis, resulting in osteopenia coupled with increased marrow adiposity.

131 ramedullary hematopoiesis, inflammation, and osteopenia, demonstrating that aberrant myelopoiesis dri

132 ate were reviewed retrospectively for severe osteopenia, dense zones of provisional calcification, in

133 overexpression of Dkk1 in osteoblasts causes osteopenia, disruption of the hematopoietic stem cell (H

134 Unexpectedly, these mice exhibited severe osteopenia due to a marked decrease in osteoblast number

135 progenitor cells with Osx1-Cre caused severe osteopenia due to abnormal maturation of osteoblasts.

136 ions in mice with either normal bone mass or osteopenia due to defective osteoblastogenesis increased

137 causes craniofacial dysmorphism, arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due t

138 kin hypersensitivity, vasomotor instability, osteopenia, edema, and abnormal sweating-are explicable

139 phosis, severe muscle wasting, hypogonadism, osteopenia, emphysema, uncoordinated movement, T cell dy

140 Osteopenia encompasses a wide range of fracture risks; a

141 X) mice exhibit cancellous and cortical bone osteopenia, enhanced osteoclastogenesis, and increased b

142 s (eg, the use of bisphosphonates for severe osteopenia) for optimized outcomes.

143 racterized by rapidly remodeling woven bone, osteopenia, fractures, and progressive skeletal deformit

144 rategy that involved treatment of women with osteopenia had an ICER less than $100,000 per QALY.

145 am-operated, and 5 weeks after surgery, when osteopenia had developed, several parameters were analyz

146 Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and

147 9 patients (10%), osteonecrosis and moderate osteopenia in 2 patients each (2%), subclinical pulmonar

148 ents had decreased bone mineral density with osteopenia in 24 patients and osteoporosis in 13 patient

149 ne mineral density was detected in 2/8 case, osteopenia in 4/8 and osteoporosis in 2/8 patients.

150 We found that deletion of Bmpr1b resulted in osteopenia in 8-week-old male mice, and the phenotype wa

151 herapy (ERT) for the treatment of GD-related osteopenia in adults, but it cannot be expected to impro

152 ntiation of the various disorders that cause osteopenia in children.

153 A-induced muscle paralysis caused pronounced osteopenia in control mice, but bone mass was preserved

154 s of the osteoblast lineage exhibited severe osteopenia in cortical and trabecular bones.

155 We show that the trabecular and cortical osteopenia in Cpdm mice is solely explained by impaired

156 ted TGF-beta signaling is the major cause of osteopenia in Esl-1(-/-) mice.

157 m, low-dose methotrexate (MTX) causes severe osteopenia in female rats.

158 Altogether, these results suggest that osteopenia in GPR103-/- mice may be mediated directly by

159 to the higher prevalence of osteoporosis and osteopenia in HIV-infected individuals.

160 Mice with a null mutation of P2X7R have osteopenia in load bearing bones, suggesting that the P2

161 dinal DEXA study demonstrated age-associated osteopenia in MAGP1Delta animals and muCT confirmed redu

162 numbers of osteoclasts contribute to severe osteopenia in Me(v)/Me(v) mice due to mutation of SHP-1.

163 ndings shed new light on the pathogenesis of osteopenia in MFS, in addition to arguing for a multifac

164 reduce serum cholesterol and protect against osteopenia in ovariectomized (OVX) rats without estrogen

165 ring PI capable of preventing development of osteopenia in patients currently on HAART.

166 tribute to an increased risk of osteoporosis/osteopenia in patients with asthma and suggests recommen

167 nexpectedly, probiotics reversed hypogonadal osteopenia in sex steroid-deficient mice by preventing t

168 6 months earlier was normal other than mild osteopenia in the femoral neck (T score, -1.3).

169 latively short-term study, MMF did not cause osteopenia in the rat model, but the suppressed bone gla

170 rated osteoclastogenesis in vitro as well as osteopenia in vivo.

171 ne successfully abates muscle catabolism and osteopenia induced by severe burn.

172 n of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over

173 We report that osteopenia is a prominent and previously unappreciated c

174 Osteopenia is a reduction in bone mass due to an imbalan

175 This osteopenia is characterized both by decreased osteoblast

176 ionally display low bone mass, and that this osteopenia is corrected by Tnf deletion.

177 Osteopenia is not a disease and the label can cause unne

178 are presented which suggest that severity of osteopenia is related to loss of alveolar crestal height

179 associated with osteoporosis and age-related osteopenia is well known clinically.

180 Systemic osteopenia is, at best, only a weak risk factor for peri

181 Reduced bone mineral density (osteopenia) is a poorly characterized manifestation of p

182 mbranous bone deposition and mineralization (osteopenia) is coupled to enhanced osteolytic resorption

183 spite the clinical importance of cholestatic osteopenia, little is known about its pathophysiologic m

184 In addition, the high prevalence of osteopenia (low bone mass) in the general population pla

185 for search included terms for osteoporosis, osteopenia, low bone density, and the drugs listed in th

186 lammatory disease [decreased lean body mass, osteopenia, low-grade anemia, decreased serum albumin an

187 clinical features are pustular rash, marked osteopenia, lytic bone lesions, respiratory insufficienc

188 Recent research suggests that osteopenia may be a predisposing factor for periodontal

189 from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed

190 roduce defective type I collagen, leading to osteopenia, multiple fractures, severe bony deformities

191 ar spine z scores that met the definition of osteopenia (n = 3) or osteoporosis (n = 2) in the early

192 Images showed severe osteopenia (n = 8), dense zones of provisional calcifica

193 effects have also been described, including osteopenia, neurocognitive impairment, and increased vas

194 These results suggest that the osteopenia observed in response to metabolic acidosis in

195 Osteopenia occurs where the rate of bone resorption exce

196 erexpressing Zfp521 also reverses the severe osteopenia of adult Runx2 transgenic mice.

197 ned over we would understand much more about osteopenia of old age.

198 ed showed no differentiation on quantitative osteopenia of the femur.

199 All had osteopenia of the lumbar spine or hip, as demonstrated b

200 steopenia, 167 with sarcopenia only, 48 with osteopenia only, and 161 with no radiologic indicators.

201 l bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bo

202 evelopmental phenomenon that is unrelated to osteopenia or mechanical stress on the spine.

203 honate therapy was added for candidates with osteopenia or osteoporosis (T score <1).

204 reatment option for patients at high risk of osteopenia or osteoporosis who are not suitable for NtRT

205 Most transplant referrals suffered from osteopenia or osteoporosis, and 29% of transplant referr

206 In end-stage lung disease patients with osteopenia or osteoporosis, bisphosphonate therapy shoul

207 ore likely to have BMD loss that may lead to osteopenia or osteoporosis.

208 rauma patients in this study had sarcopenia, osteopenia, or both.

209 ted by the variety of methods used to assess osteopenia, oral bone mass, and periodontitis, as well a

210 etal complications of HIV and HAART, such as osteopenia, osteonecrosis, and infection continue to be

211 order to assess different bone pathologies (osteopenia, osteoporosis and osteomyelitis) in an effect

212 of cardiovascular disease, type 2 diabetes, osteopenia, osteoporosis, and chronic hepatitis, as well

213 children and will precipitate and exacerbate osteopenia, osteoporosis, and fractures in adults.

214 alth in patients with breast cancer, causing osteopenia, osteoporosis, and fractures.

215 le side effects on bone structure, including osteopenia, osteoporosis, and increased incidence of bon

216 Osteopenia, osteoporosis, and low bone mineral density a

217 n oral mode of delivery for the treatment of osteopenia, osteoporosis, and Paget's disease of bone.

218 ision of physical examination for diagnosing osteopenia, osteoporosis, or spinal fracture.

219 Extraintestinal manifestations included osteopenia/osteoporosis (52%), anemia (34%), cryptogenic

220 resented with a better accuracy in excluding osteopenia/osteoporosis (specificity), since patients wi

221 Patients were categorized as having osteopenia/osteoporosis (T score less than or equal to -

222 No association between lumbar spine osteopenia/osteoporosis and radiographic score was found

223 ic score at 3 years disease in patients with osteopenia/osteoporosis of the femoral neck was twice th

224 the influence of serum estradiol levels and osteopenia/osteoporosis on common clinical measurements

225 The impact of estrogen deficiency and osteopenia/osteoporosis on periodontitis is unclear, par

226 easured yearly by 125I radioimmunoassay, and osteopenia/osteoporosis was determined by dual energy x-

227 inflammatory bowel disease (IBD)-associated osteopenia/osteoporosis.

228 Low-weight patients are at high risk for osteopenia/osteoporosis.

229 megaly, growth and pubertal retardation, and osteopenia/osteoporosis.

230 ar bone protection in ovariectomized-induced osteopenia (OVX) rats as determined by assay when admini

231 Mice deficient in SIRT3 exhibited severe osteopenia owing to increased numbers of osteoclasts.

232 tected in 77.1% of females with osteoporosis/osteopenia (P >0.05).

233 n male but not female mice, whereas cortical osteopenia persisted in both sexes.

234 ults in immune tolerance and ameliorates the osteopenia phenotype in OVX mice.

235 osteoblastogenesis may be the cause for the osteopenia phenotype of FACC1KO bone homeostasis.

236 monitoring bone status with DEXA scans, the osteopenia potential of low doses of prednisone will be

237 ull and ODDD mutant mice develop age-related osteopenia, primarily due to a progressive enlargement o

238 All TG lines showed evidence of osteopenia, ranging from mild to severe, as evidenced by

239 els of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiol

240 d murine model of accelerated senescence and osteopenia (SAMP6) to test the hypothesis that reduced o

241 tration of bisphosphonate therapy to prevent osteopenia secondary to malignancy in one patient.

242 ramen provided an advantage in patients with osteopenia, severe osteoarthritis, and scoliosis compare

243 If she has osteopenia, should she be treated with a bisphosphonate?

244 lammation is characterized by bone erosions, osteopenia, soft-tissue swelling, and uniform joint spac

245 ibit growth retardation and severe postnatal osteopenia stemming at least in part from abnormally acc

246 orld Health Organization criteria, 39.6% had osteopenia (T score of -1 to -2.49) and 7.2% had osteopo

247 oral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49) and with no history

248 tients had a lower risk for osteoporosis and osteopenia than female patients (OR 0.45; 95% CI 0.29 to

249 suggest a novel therapeutic approach to HIV osteopenia through modulation of these two molecules.

250 GH replacement, cardiovascular risk factors, osteopenia, thyroid problems, and gonadal damage resulti

251 The relationship of osteopenia to oral bone loss and periodontal disease has

252 1 expression in muscle but not bone restored osteopenia to wt levels without improving diabetes.

253 cent bone mineral density screening revealed osteopenia, total hip T score of -1.8.

254 95% confidence interval [CI], 3.59-4.53) and osteopenia was associated with a 1.8-fold higher rate (9

255 ere performed, and a history of osteoporosis/osteopenia was collected.

256 sphosphonates for those with osteoporosis or osteopenia was dominated.

257 recipients, we observed that osteoporosis or osteopenia was present in 88% of patients.

258 or hip was diagnosed in 44% of patients and osteopenia was present in an additional 44%.

259 utions of osteoclasts and osteoblasts to HCS osteopenia, we created a conditional-by-inversion (Notch

260 d probiotic treatment against postmenopausal osteopenia.We used a novel red clover extract (RCE) rich

261 08 who survived to discharge, sarcopenia and osteopenia were associated with higher risks of 1-year m

262 Osteoporosis and osteopenia were defined as T-scores </= -2.5 and -1.0 to

263 Women with osteopenia were excluded.

264 pausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or plac

265 at loss of Spop results in brachydactyly and osteopenia, which can be rescued by reducing the dosage

266 s conducted in 171 postmenopausal women with osteopenia, who were recruited from Lubbock County, Texa

267 Bgn-deficient mice develop age-related osteopenia with a phenotype that resembles osteoporosis

268 ion of early lineage macrophages resulted in osteopenia with blunted effects of PTH anabolic actions,

269 nversely, Trap-Atf4-tg mice displayed severe osteopenia with dramatically increased osteoclastogenesi

270 e, we showed that W(sh)/W(sh) mice exhibited osteopenia with elevated bone resorption and bone format

271 e show that Esl-1(-/-) mice exhibit a severe osteopenia with elevated bone resorption and decreased b

272 Fzd8-deficient mice displayed osteopenia with normal bone formation and increased oste

273 Loss of beta-catenin produced severe osteopenia with striking increases in osteoclasts, where